


1 / 23

**FIGURE 1**





FIGURE 2



FIGURE 3

rhRLx Treatment Results in Long Term Decreases in Blood Pressure in Hypertensive Subjects

**FIGURE 4**





FIGURE 5

6/23

**FIGURE 6**

Moderate or Marked Improvement in Dyspnea

SBP > Median (Table 2.6.4)




FIGURE 7

Moderate or Marked Improvement in Dyspnea

CrCl < Median (Table 2.6.7)




FIGURE 8

Dyspnea Relief in Patients with Elevated Brain Natriuretic Peptide Levels




FIGURE 9

Dyspnea Relief in Hypertensive Patients




FIGURE 10

Dyspnea Relief in Patients with Reduced Creatine Clearance




FIGURE 11




FIGURE 12





FIGURE 13

**FIGURE 14**





FIGURE 15

**B Median Loop Diuretic Dose
Administered to Day 5**



**A Median Body Weight
Change at Day 14 (kg)**




FIGURE 16




FIGURE 17

Cardiovascular Death or Heart Failure/Renal Re-Hospitalizations
(Kaplan Meier Estimates)




FIGURE 18




FIGURE 19




FIGURE 20





FIGURE 21



Relaxin Causes Vasodilation in the Presence of Vasoconstriction

FIGURE 22




FIGURE 23